Canine leishmaniosis: In vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum

Parasitology Research

Volumn 110, Issue 6, 2012, Pages 2509-2513

  Farca, Anna Maria ^a   Miniscalco, B ^a   Badino, P ^a   Odore, R ^a   Monticelli, P ^a   Trisciuoglio, A ^a   Ferroglio, E ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; MARBOFLOXACIN; MILTEFOSINE;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; LEISHMANIA INFANTUM; NONHUMAN; PRIORITY JOURNAL;

ALLOPURINOL; ANIMALS; ANTIPROTOZOAL AGENTS; DOG DISEASES; DOGS; DRUG SYNERGISM; FLUOROQUINOLONES; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; PHOSPHORYLCHOLINE;

CANIS FAMILIARIS; LEISHMANIA INFANTUM;

EID: 84863480233     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-011-2792-7     Document Type: Article

References (37)

1. Arthur G, Bittman R (1998) The inhibition of cell signalling pathways by anti-tumour ether lipids. Biochim Biophys Acta 1390:85-102 (Pubitemid 28122329)
2. Aste G, Di Tommaso M, Steiner JM (2005) Pancreatitis associated with N-methylglucamine therapy in a dog with leishmaniosis. Vet Res Comm 29(2):269-272 (Pubitemid 41631410)
3. Badolato R, Sacks DL, Savoia D, Musso T (1996) Leishmania major: infection of human monocytes induces expression of IL-8 and MCAF. Exp Parasitol 82:21-26 (Pubitemid 26114860)
4. Baneth G, Shaw SE (2002) Chemotherapy of canine leishmaniosis. Vet Parasitol 106(4):315-324 (Pubitemid 34655456)
5. Barratt G, Saint-Pierre-Chazalet M, Loiseau PM (2009) Cellular transport and lipid interactions of miltefosine. Curr Drug Metab 10:247-255
6. Berkovic C, Grunwald U, Menzel W, Unger C, Hiddemann W, Fleer EA (1995) Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumor cells. Eur J Cancer 31:2080-2085 (Pubitemid 26024300)
7. Bianciardi P, Fasanella A, Foglia Manzillo V, Trotta T, Pagano A, Sorino S, Gradoni L, Oliva G (2004) The efficacy of enrofloxacin, alone or combined with metronidazole, in the therapy of canine leishmaniasis. Parasitol Res 93:486-492. doi:10.1007/s00436-004-1170-0 (Pubitemid 39222526)
8. Bianciardi P, Brovida C, Valente M, Aresu L, Cavicchioli L, Vischer C, Giroud L, Castagnaro M (2009) Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys. Toxicol Pathol 37(6):770-775
9. Cavaliero T, Arnold P, Mathis A, Glaus T (1999) Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum. J Vet Intern Med 13(4):330-334
10. Chakraborty AK, Majumder HK (1993) A type 1DNA topoisomerase from the kinetoplast hemoflagellate Leishmania donovani. Biochem Biophys Res Commun 30:257-263
11. Denerolle P, Bourdoiseau G (1999) Combination allopurinol and anti-294 mony treatment versus antimony alone and allopurinol alone in 295 the treatment of canine leishmaniasis (96 cases). J Vet Intern Med 296 13(5):413-415
12. Ferreira JM, Guerra JA, Magalhães BM, Coelho LI, Maciel MG, Barbosa MG (2009) Chronic chagasic cardiopathy in Amazon region: an etiology to remember. Arq Bras Cardiol 93(6):e93-95, e107-109
13. Gramiccia M, Gradoni L (2005) The current status of zoonotic leishmaniases and approaches to disease control. Int J Parasitol 35(11-12):1169-1180 (Pubitemid 41395178)
14. Ikeda-Garcia FA, Lopes RS, Ciarlini PC et al (2007) Evaluation of renal and hepatic functions in dogs naturally infected by visceral leishmaniosis submitted to treatment with meglumine antimoniate. Res Vet Sci 83:105-108 (Pubitemid 46648008)
15. Luz RI, Vermeersch M, Dujardin JC, Cos P, Maes L (2009) In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells. Antimicrob Agents Chemother 53(12):197-203
16. Mandal G, Sarkar A, Saha P, Singh N, Sundar S, Chatterjee M (2009) Functionality of drug efflux pumps in antimonial resistant Leishmania donovani field isolates. Indian J Biochem Biophys 46 (1):86-92
17. Manna L, Gravino AL, Picillo E, Decaro N, Buonavoglia C (2008) Leishmania DNA quantification by real-time PCR in naturally infected dogs treated with miltefosine. Ann N Y Acad Sci 1149:358-360
18. Manna L, Vitale F, Reale S, Picillo E, Neglia G, Vescio F, Gravino AE (2009) Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis. Vet J 182(3):441-445
19. Maroli M, Gradoni L, Oliva G, Castagnaro M, Crotti A, Lubas G, Paltrinieri S, Roura X, Zini E, Zatelli A (2010) Guidelines for prevention of leishmaniasis in dogs. J Am Vet Med Assoc 236 (11):1200-1206
20. Mateo M, Maynard L, Vischer C, Bianciardi P, Mirò G (2009) Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis. Parasitol Res 105:155-162
21. Miró G, Oliva G, Cruz I, Cañavate C, Mortarino M, Vischer C, Bianciardi P (2009) Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. Vet Dermatol 20(5-6):397-404
22. Noli C, Auxilia ST (2005) Treatment of canine Old World visceral leishmaniasis: a systematic review. Vet Dermatol 16 (4):213-232 (Pubitemid 41265192)
23. Prescott JF, Baggot DJ, Walker RD (2000) Fluoroquinolones. In: Giguère S et al (eds) Antimicrobial therapy in veterinary medicine, 3rd edn. Iowa State University Press/Ames, Iowa, pp 315-338
24. Pujals G, Suñé-Negre JM, Pérez P, García E, Portus M, Tico JR, Miñarro M, Carrió J (2008) In vitro evaluation of the effectiveness and cytotoxicity of meglumine antimoniate microspheres produced by spray drying against Leishmania infantum. Parasitol Res 102:1243-1247. doi:10.1007/s00436-008-0901-z
25. Raether W, Seidenath H, Hofmann J (1989) Potent antibacterial fluoroquinolones with marked activity against Leishmania donovani in vivo. Parasitol Res 75:412-413 (Pubitemid 19111471)
26. Rougier S, Vouldoukis I, Fournel S, Pérès S, Woehrlé F (2008) Efficacy of different treatment regimens of marbofloxacin in canine visceral leishmaniosis: a pilot study. Vet Parasitol 153:244-254
27. Roura X (2010) Treatment of canine leishmaniosis. Proc of 2nd International Congress on Canine Leishmaniosis, 79-93
28. Seifert K, Escobar P, Croft SL (2010) In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J Antimicrob Chemother 65(3):508-511
29. Slunt KM, Grace JM, MacDonald TL, Pearson RD (1996) The effect of mitonafide analogs on topoisomerase II of Leishmania chagasi. Antimicrob Agents Chemother 40:706-709 (Pubitemid 26071539)
30. Torres M, Bardagi M, Roura X, Zanna G, Ravera I, Ferrer L (2011) Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol. Vet J 188(3):346-351. Epub 2010
31. Unger C, Damenz W, Fleer EA, Kim DJ, Breiser A, Hilgard P, Engel J, Nagel G, Eibl H (1989) Hexadecylphosphocholine, a new ether lipid analogue: studies on the anti-neoplastic activity in vitro and in vivo. Acta Oncol 28:213-217 (Pubitemid 19159628)
32. Vermeersch M, da Luz RI, Toté K, Timmermans JP, Cos P, Maes L (2009) In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother 53(9):3855-3859
33. Vouldoukis I, Drapier JC, Nussler AK, Tselentis Y, Da Silva OA, Gentilini M, Mossalayi DM, Monjour L, Dugas B (1996) Canine visceral leishmaniasis: successful chemotherapy induces macrophage antileishmanial activity via the L-arginine nitric oxide pathway. Antimicrob Agents Chemother 40:253-256 (Pubitemid 26019708)
34. Vouldoukis I, Rougier S, Dugas B, Pino P, Mazier D, Woehrlè F (2006) Canine visceral leishmaniasis: comparison of in vitro activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate. Vet Parasitol 135:137-146 (Pubitemid 43003540)
35. Wadhone P, Maiti M, Agarwal R, Kamat V, Martin S, Saha B (2009) Miltefosine promotes IFN-dominated anti-leishmanial immune response. J Immunol 182:7146-7154
36. Yoon S, Kim H, Lee Y, Kim S (2011) Bacteremia caused by Corynebacterium amycolatum with a novel mutation in gyrA gene that confers high-level quinolone resistance. Korean J Lab Med 31(1):47-48
37. Zhang R, Shang L, Jin H, Ma C, Wu Y, Liu Q, Xia Z, Wei F, Zhu XQ, Gao H (2010) In vitro and in vivo antileishmanial efficacy of nitazoxanide against Leishmania donovani. Parasitol Res. doi:10.1007/s00436-010-1906-y